A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2013
At a glance
- Drugs Topotecan (Primary)
- Indications CNS cancer; Leukaemia; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Therapeutic Use
- 05 Oct 2009 Additional lead trial investigators identified as reported by New Jersey Cancer Trial Connect record.
- 08 Nov 2006 Status change
- 22 Aug 2005 New trial record.